Dyal, Owl Rock explore strategic combination, Riverside Partners building cybersecurity services platform, York Capital makes growth investment in F1 Payments

The Wire

Dec. 3, 2020

Dyal, Owl Rock explore strategic combination, Riverside Partners building cybersecurity services platform, York Capital makes growth investment in F1 Payments

This seems huge - Dyal Capital Partners is reportedly exploring combining with Owl Rock Capital Partners, the firms announced in a statement last night. The statement came after a story in WSJ by PE scoopster Miriam Gottfried and Cara Lombardo. Owl Rock, Dyal and Dyal backer Neuberger Berman would all have ownership stakes in the combined entity, the statement said.

WSJ said the deal will also include SPAC firm Altimar Acquisition Corp. What have you heard? Hit me up at [email protected].

...Read the full Wire commentary on PE Hub.

And as always, write to me at [email protected] with any tips, feedback or just to say hello.

We hope you’re enjoying the new streamlined PE Hub Wire. For a more detailed version, we have launched a new premium version for our paying PE Hub subscribers that is ad-free and includes full editorial commentary and descriptions with each story. For more information about the Wire Premium, reach out to [email protected].

Note to Readers: It's that time of year ... for the 21st time, the editors of PE Hub and Buyouts honor exceptional buyouts with our Deal of the Year Awards.

Winners are chosen in seven categories: Deal of the Year, Large-Market Deal of the Year, Middle-Market Deal of the Year, Small-Market Deal of the Year, Turnaround of the Year, International Deal of the Year, and Secondaries Deal of the Year.

Go here for more information and to read about rules and methodology. Also check out past winners. Last year, New Mountain took the crown with its exit of Equian.

If you have additional questions, email Private Equity Editor Chris Witkowsky at [email protected].

Also of note (may require subscriptions)

Secondary: ICG Strategic Equity is lead backer in a single-asset secondary involving Curium Pharma, a portfolio company of CapVest Equity Partners III. Read it here on Secondaries Investor.